Stölzel F, Stelljes M, Beelen DW, Markiewicz M, Reményi P, Luft T, Ciceri F, Wagner-Drouet E-M, Junghanss C, Scheid C, Patriarca F, Socié G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlović J, Schild B, Khan I, Li X, Bethge W. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. Haematologica; https://doi.org/10.3324/haematol.2025.288770 [Early view].